|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SGLT2 inhibitor empagliflozin was shown to reduce HF admissions and cardiovascular mortality in patients with prior cardiovascular disease including HF.
|
27653447 |
2017 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with type II DM, SGLT-2 inhibitors appeared to reduce both all-cause and cardiovascular mortality, primarily due to reduction in the risk of heart failure.
|
27866027 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
A growing body of clinical evidence from those trials is now accumulating, and empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has first demonstrated significant risk reduction, relative to placebo, in CV death, overall mortality, and hospitalization for worsened heart failure in high-risk patients with diabetes mellitus.
|
28043708 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the only completed trial to date to assess a sodium-glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin reduced the risk of composite cardiovascular endpoints, predominantly through its impact on cardiovascular mortality and heart failure hospitalization.
|
28291655 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin was recently reported to reduce heart failure-associated hospitalizations and cardiovascular mortality amongst individuals with type 2 diabetes at high cardiovascular risk.
|
28391552 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
A recent cardiovascular (CV) safety trial, the EMPA-REG OUTCOME trial, showed that empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, markedly reduced CV death and all-cause mortality and hospitalization for heart failure in patients with T2DM and established CV disease (CVD).
|
28403850 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, current clinical data demonstrated that treatment with the sodium glucose cotransporter 2 inhibitor empagliflozin reduced hospitalization for heart failure in patients with type 2 diabetes mellitus and high cardiovascular risk.
|
28526183 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study demonstrated for the first time that a glucose-lowering agent, the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, could reduce major adverse cardiovascular events, cardiovascular mortality, hospitalization for heart failure, and overall mortality when given in addition to standard care in patients with T2DM at high cardiovascular risk.
|
28526185 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, current clinical data demonstrated that treatment with the sodium glucose cotransporter 2 inhibitor empagliflozin reduced hospitalization for heart failure in patients with type 2 diabetes mellitus and high cardiovascular risk.
|
28606342 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study demonstrated for the first time that a glucose-lowering agent, the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, could reduce major adverse cardiovascular events, cardiovascular mortality, hospitalization for heart failure, and overall mortality when given in addition to standard care in patients with T2DM at high cardiovascular risk.
|
28606344 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first CV outcome study terminated with empagliflozin, a specific SGLT2 inhibitor, has shown a reduction in CV mortality and in heart failure hospitalization, suggesting a beneficial impact on cardiac function which remains to be demonstrated.
|
28643218 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is likely that all SGLT2 inhibitors will receive an indication for secondary prevention of heart failure; whether the agents should be used in primary prevention is a much more difficult question, because it would require a very large study of patients without heart disease.
|
28692750 |
2017 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Beneficial effects on kidney disease progression, cardiovascular and all-cause mortality, and hospitalization for heart failure have also been demonstrated with one SGLT2 inhibitor (empagliflozin).
|
28721687 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective was to assess relative risk of heart failure hospitalization of sodium-glucose co-transporter-2 (SGLT2) and dipeptidyl peptidase-4 (DPP4) inhibitors in T2DM patients.
|
28756774 |
2017 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with other glucose-lowering drugs, use of SGLT2 inhibitors was associated with decreased risk of cardiovascular mortality (HR 0·53 [95% CI 0·40-0·71]), major adverse cardiovascular events (0·78 [0·69-0·87]), and hospital events for heart failure (0·70 [0·61-0·81]; p<0·0001 for all).
|
28781064 |
2017 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, the EMPA-REG OUTCOME trial revealed that empagliflozin, an inhibitor of the sodium-glucose cotransporter 2 (SGLT2), substantially reduced the risk of hospitalization for heart failure, death from cardiovascular causes, and all-cause mortality in patients with type 2 diabetes mellitus at high cardiovascular risk.
|
29016751 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
|
29024278 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the effect of SGLT2 inhibitors when used in combination with a loop diuretic, the RECEDE-CHF (Renal and Cardiovascular Effects of SGLT2 inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure) trial is a single-centre, randomised, double-blind, placebo-controlled, cross-over trial conducted in a secondary care setting within NHS Tayside, Scotland.
|
29042392 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accordingly, in this review, we summarize the key pharmacodynamic effects of SGLT2 inhibitors and the clinical evidence that support the rationale for the use of SGLT2 inhibitors in patients with HF who have T2D.
|
29061576 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will summarize key findings of the impact of glucose-lowering agents on CV safety and HF-associated outcomes, present available data on the underlying mechanisms for the benefits of the SGLT2 inhibitors on HF, and discuss strategies to improve outcomes in patients with DM and high CV risk.
|
29270818 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
We particularly favour SGLT2 inhibitors in those where additional weight loss and blood pressure reductions are desired, and in patients with heart failure or cardiovascular disease.
|
29320602 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The remarkable reduction in cardiovascular (CV) mortality (38%), major CV events (14%), hospitalization for heart failure (35%), and death from any cause (32%) observed over a period of 2.6 years in patients with T2D and high CV risk in the EMPA-REG OUTCOME trial involving the SGLT2 inhibitor empagliflozin (Empa) have raised the possibility that potential novel, more specific mechanisms of SGLT2 inhibition synergize with the known modest systemic improvements, such as glycemic, body weight, diuresis, and blood pressure control.
|
29322280 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Trial sequential analysis provided firm evidence of a 20% reduction in major adverse cardiac events, all-cause mortality, and hospitalization for heart failure with SGLT2 inhibitors, but evidence remains inconclusive for cardiovascular mortality.
|
29353233 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ongoing clinical trials with SGLT2 inhibitors in heart failure are positioned to confirm or refute the hypothesis that these drugs may favourably influence the course of obesity-related HFpEF by their ability to attenuate the secretion and actions of leptin.
|
29359851 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
These effects may contribute to the protective effects of SGLT2 inhibitors on blood pressure and heart failure observed in diabetic patients with chronic kidney diseases.
|
29361669 |
2018 |